Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 30, Issue 5, 2008, Pages 415-422

  Okura, Takafumi ^a   Watanabe, Sanae ^a   Kurata, Mie ^a   Koresawa, Mitsuko ^a   Irita, Jun ^a   Enomoto, Daijiro ^a   Jotoku, Masanori ^a   Miyoshi, Ken Ichi ^a   Fukuoka, Tomikazu ^a   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Arterial stiffness; Intima media thickness; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTITHROMBOCYTIC AGENT; STATIN; VALSARTAN;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON CAROTID ARTERY; CORONARY ARTERY DILATATION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEMODYNAMICS; HUMAN; LONG TERM CARE; MALE; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULTRASOUND; VASCULAR RESISTANCE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD FLOW VELOCITY; CAROTID ARTERY, COMMON; ELASTICITY; FEMALE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; TUNICA MEDIA; VALINE; VASCULAR RESISTANCE;

EID: 47549083291     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802279108     Document Type: Article

References (30)

1. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.
2. Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, Fukunaga R, Yoneda S, Kimura K, Kamada T. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990;21:1567-1572.
3. Roman MJ, Pickering TG, Pini R, Schwartz JE, Devereux RB. Prevalence and determinants of cardiac and vascular hypertrophy in hypertension. Hypertension 1995;26:369-373.
4. Jiang YN, Kohara K, Hiwada K. Alteration of carotid circulation in essential hypertensive patients with left ventricular hypertrophy. J Hum Hypertens 1998;12:173-179.
5. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intimamedia thickness and arterial stiffness: Indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999;100:951-957.
6. Smilde TJ, van den Berkmortel FW, Boers GH, Wollersheim H, de Boo T, van Langen H, Stalenhoef AF. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1998;18:1958-1963.
7. Michel JB, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, Corman B, Levy BI. Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries. Am J Physiol 1994;267:R124-R135.
8. Emoto M, Nishizawa Y, Kawagishi T, Maekawa K, Hiura Y, Kanda H, Izumotani K, Shoji T, Ishimura E, Inaba M, Okuno Y, Morii H. Stiffness indexes beta of the common carotid and femoral arteries are associated with insulin resistance in NIDDM. Diabetes Care 1998;21:1178-1182.
9. Kawasaki T, Sasayama S, Yagi I, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 1987;21:678-687.
10. Hirai T, Sasayama S, Kawasaki T, Yagi S. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989;80:78-86.
11. Kurata M, Okura T, Watanabe S, Higaki J. Association between carotid hemodynamics and asymptomatic white and gray matter lesions in patients with essential hypertension. Hypertens Res 2005;28:797-803.
12. Okura T, Watanabe S, Miyoshi K, Fukuoka T, Higaki J. Intrarenal and carotid hemodynamics in patients with essential hypertension. Am J Hypertens 2004;17:240-244.
13. Watanabe S, Okura T, Kitami Y, Hiwada K. Carotid hemodynamic alterations in hypertensive patients with insulin resistance. Am J Hypertens 2002;15:851-856.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000;342:145-153.
16. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006;29 (Suppl.): S1-S105.
17. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: Indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999;100:951-957.
18. Jiang Y, Kohara K, Hiwada K. Low wall shear stress in carotid arteries in subjects with left ventricular hypertrophy. Am J Hypertens 2000;13:892-898.
19. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: Regulation, signaling and function. Blood Press 2003;12:70-88.
20. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-128.
21. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149-154.
22. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
23. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-861.
24. Manabe S, Okura T, Watanabe S, Higaki J. Association between carotid haemodynamics and inflammation in patients with essential hypertension. J Hum Hypertens 2005;19:787-791.
25. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmcol 2005;46:735-739.
26. Ichihara A, Hayashi M, Koura Y, Tada Y, Hirota N, Saruta T. Long-term effects of intensive blood pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 2003;16:959-965.
27. Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, Stanton A, Hughes A, Thom S. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006;37:2381-2384.
28. Mortsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intimamedia thickness in hypertensive patients when compared with atenolol: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007;261:472-429.
29. Safar ME, Boudier HS. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension 2005;46:205-209.
30. Okura T, Watanabe S, Kurata M, Manabe S, Koresawa M, Irita J, Enomoto D, Miyoshi K, Fukuoka T, Higaki J. Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 2007;30:335-340.